Genmab Stock Nasdaq Copenhagen
Stocks
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 126B 19.45B 16.79B 15.8B 14.37B 27.02B 1,861B 27.45B 185B 72.56B 933B 73.04B 71.45B 3,103B | P/E 2026 * |
26.6x | P/E 2027 * | 18.7x |
|---|---|---|---|---|---|
| Enterprise Value | 145B 22.49B 19.41B 18.27B 16.62B 31.24B 2,152B 31.74B 214B 83.89B 1,078B 84.44B 82.6B 3,588B | EV / Sales 2026 * |
5.01x | EV / Sales 2027 * | 4.06x |
| Free-Float |
95.42% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab
| 1 day | -0.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.33% | +4.14% | - | - | 19.46B | |
| +0.17% | +3.62% | +70.94% | +109.68% | 73.25B | |
| +1.73% | +13.43% | +57.10% | +90.54% | 61.95B | |
| +0.11% | -4.67% | +0.52% | +484.71% | 28.02B | |
| +5.24% | +5.33% | +57.01% | +17.77% | 24.15B | |
| +1.26% | -0.05% | -18.30% | -18.08% | 23.01B | |
| -0.71% | +5.26% | +241.94% | +427.03% | 18.35B | |
| 0.00% | +5.62% | +40.50% | -15.26% | 19.46B | |
| +3.83% | +2.65% | +25.00% | +592.85% | 15.92B | |
| +1.53% | +0.30% | +38.66% | +152.95% | 12.96B | |
| Average | +1.28% | +1.24% | +57.04% | +204.69% | 30.79B | |
| Weighted average by Cap. | +1.15% | +3.43% | +57.13% | +166.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29.01B 4.49B 3.88B 3.65B 3.32B 6.24B 430B 6.34B 42.77B 16.76B 215B 16.87B 16.5B 717B | 33.71B 5.22B 4.5B 4.24B 3.86B 7.25B 499B 7.37B 49.69B 19.47B 250B 19.6B 19.17B 833B |
| Net income | 4.94B 765M 660M 622M 565M 1.06B 73.21B 1.08B 7.28B 2.85B 36.68B 2.87B 2.81B 122B | 7.17B 1.11B 959M 902M 821M 1.54B 106B 1.57B 10.57B 4.14B 53.25B 4.17B 4.08B 177B |
| Net Debt | 19.62B 3.04B 2.62B 2.47B 2.25B 4.22B 291B 4.29B 28.92B 11.33B 146B 11.41B 11.16B 485B | 11.13B 1.72B 1.49B 1.4B 1.27B 2.39B 165B 2.43B 16.41B 6.43B 82.62B 6.47B 6.33B 275B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
